Increased Expression of Matrix Metalloproteinase 9 Correlates with Poor Prognostic Variables in Renal Cell Carcinoma

European Urology

Volumn 44, Issue 5, 2003, Pages 560-566

  Cho, Nam Hoon ^a   Shim, Hyo Sub ^a   Rha, Sun Young ^a   Kang, Suki Hee ^a   Hong, Sung Hui ^a   Choi, Young Deuk ^a   Hong, Sung Jun ^a   Cho, Sang Ho ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

cDNA array; MMP2; MMP9; Renal cell carcinoma; RT PCR; Zymography

Indexed keywords

COMPLEMENTARY DNA; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; ARTICLE; CHI SQUARE DISTRIBUTION; ENZYME ACTIVITY; ENZYMOLOGY; FEMALE; GENE EXPRESSION; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MAJOR CLINICAL STUDY; MALE; METABOLISM; METASTASIS; NONBIOLOGICAL MODEL; NONPARAMETRIC TEST; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; UPREGULATION; ZYMOGRAPHY;

EID: 0142166718     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00362-2     Document Type: Article

References (28)

1. Knudson AGI. Antioncogenesis and human cancer. Proc Natl Acad Sci USA 1993;90:10914-21.
2. Wagner JR, Linehan WM. Molecular genetics of renal cell carcinoma. Semin Urol Oncol 1996;14:244-9.
3. Kovacs G. Papillary renal cell carcinoma: a morphologic and cytologic study of 11 cases. Am J Pathol 1989;134:27-34.
4. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumors. J Pathol 1997;183:131-3.
5. Bostwick DG, Eble JN, Murphy GP. Conference summary: Diagnosis and prognosis of renal cell carcinoma. 1997 Workshop. Cancer 1997;80:975-6.
6. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinase in metastasis. J Natl Cancer Inst 1997;89:1260-70.
7. Egelblad M, Wertz Z. New functions for the matrix metalloproteinase in cancer progression. Nature Rev Cancer 2002;2:163-75.
8. Overall CM, Lopez C. Strategies for MMP inhibition in cacner: innovations for the post-trial era. Nature Rev Cancer 2002;2:657-72.
9. Liotta LA, Thorgeirsson UP, Garbisa S. Role of collagenases in tumor cell invasion. Cancer Metastasis Rev 1982;1:277-88.
10. Pauli BU, Schwartz DE, Thonar EJA, Kuettner KE. Tumor invasion and host extracellular matrix. Cancer Metastasis Rev 1983;2:129-52.
11. Woolley DE. Collagenolytic mechanisms in tumor cell invasion. Cancer Metastasis Rev 1984;3:361-72.
12. Duffy MJ. Do proteases play a role in cancer invasion and metastasis? Eur J Cancer Clin Oncol 1987;23:583-9.
13. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ, Ringert RH. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 1998;160:1914-8.
14. Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999;19:5902-12.
15. Miyake H, Hara I, Gohji K, Yamanaka K, Hara S, Arakawa S, et al. Relative expression of matrix metalloproteinase-2 and tissue inhibitors of metalloproteinase-2 in mouse renal cell caricnoma cells regulates their metastatic potential. Clin Cancer Res 1999;5:2824-9.
16. Lein M, Jung K, Laube C, Hubner T, Winkelmann B, Stephan C, et al. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissues of patients with renal cell carcinoma. Int J Cancer 2000;85:801-4.
17. Walther MM, Kleiner DE, Lubensky IA, Pozzatti R, Nyguen T, Gnarra JR, et al. Progelatinase A mRNA expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. Urology 1997;50:295-301.
18. Hagemann T, Gunawan B, Schulz M, Fuzesi L, Binder C. mRNA expression of matrix metalloproteinases and their inhibitors differes in subtypes of renal cell carcinomas. Eur J Cancer 2001;37:1839-46.
19. Varkarakis MJ, Bhanalaph T, Moore RH, Murphy GP. Prognostic criteria of renal cell carcinoma. J Surg Oncol 1974;6:97-107.
20. Fuhrmann SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
21. Quezado MM, Abati AD, Albuquerque AV, Wilson J, Merino MJ, Filie AC. Morphological diversity in malignant melanoma: the potential use of microdissection and the polymerase chain reaction for diagnosis. Mod Pathol 1998;11:1010-5.
22. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995;87:293-8.
23. Otani N, Tsukamoto T, Saiki I, Yoneda J, Mitaka T, Kumamoto Y. In vitro invasive potential and type IV collagenolytic activity of human renal cell carcinoma cells derived from primary and metastatic lesions. J Urol 1993;149:21182-5.
24. Chambers AF, MacDonald IC, Schmidt EE, Koop S, Morris VL, Khokha R, et al. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev 1995;14: 279-301.
25. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumor invasion and metastasis. Eur J Cancer 2000; 36:1621-30.
26. Zeng ZS, Hsuang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996;14:3133-40.
27. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, et al. Tissue levels of matrix metalloproteinase MMP2 and MMP9 are related to overall survival of patients with gastric carcinomas. Br J Cancer 1996;74:413-7.
28. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998;83:1153-62.